TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

TRACON Pharmaceuticals reports positive interim data, focuses on growth strategies

TRACON Pharmaceuticals showcased promising interim data from the ENVASARC trial, reflecting positive efficacy of ENVA treatment and strategic advancements in product development.
While facing challenges such as financial losses and regulatory compliance, TRACON's focus on cost-saving measures and operational efficiency positions it for sustainable growth.
The company's strong cash position, commitment to advancing its pipeline, and opportunities for collaboration and portfolio expansion signal a promising outlook for future growth and innovation.
By leveraging its product development platform and upcoming trial data releases, TRACON aims to drive value creation, financial stability, and regulatory compliance in the competitive pharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Tracon Pharmaceuticals Inc. TCON, -4.23% were up 29% in premarket trading on Friday after the company said it would partner with two Chinese companies to develop its investigational soft tissue sarcoma therapy in North America.

Tracon stock rises on cancer development partnerships

Company to Host Investor Conference Call Today at 8:30 a.m. ET / 5:30 a.m. PT

TRACON Pharmaceuticals, 3D Medicines and Jiangsu Alphamab Announce Partnership for Development of Subcutaneous PD-L1 Single-Domain Antibody in Soft Tissue Sarcoma

TRACON Pharmaceuticals' (TCON) CEO Charles Theuer on Q3 2019 Results - Earnings Call Transcript

SAN DIEGO, Oct.  21, 2019  (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration through our license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it has entered into a Common Stock Purchase Agreement of up to $15.0 million with Aspire Capital Fund, LLC (“Aspire Capital”). Aspire Capital has committed to purchase up to $15.0 million of shares of the Company’s common stock at TRACON’s request from time to time during a 30 month period beginning on the effective date of a registration statement related to the transaction and at prices based on the market price at the time of each sale. There are no warrants, derivatives, or other share classes associated with this agreement. Proceeds from the Agreement will be used to further advance the Company's pipeline and product development platform, as well as general corporate purposes.

TRACON Pharmaceuticals Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

SAN DIEGO, Sept.  03, 2019  (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration through our license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright in New York on Monday, September 9th, at 3:50pm EDT.

TRACON Pharmaceuticals to Present at the Rodman & Renshaw 21st Annual Global Investment Conference Sponsored by H.C. Wainwright

SAN DIEGO, Aug.  29, 2019  (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration through our license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present at the 2019 Wells Fargo Securities Healthcare Conference in Boston on Thursday, September 5th, at 1:55 PM EDT.

TRACON Pharmaceuticals to Present at the 2019 Wells Fargo Securities Healthcare Conference

SAN DIEGO, Aug.  28, 2019  (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration through our license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present at the 4th annual Disruptive Growth Conference in New York on Wednesday, September 4th, at 1:40 PM EDT.

TRACON Pharmaceuticals to Present at the RHK Capital 4th annual Disruptive Growth Conference hosted by Reed Smith

TRACON Pharmaceuticals Inc. (TCON) CEO Charles Theuer on Q2 2019 Results - Earnings Call Transcript

Shares of the thinly traded nanocap biotech TRACON Pharmaceuticals Inc (NASDAQ: TCON) were rallying Thursday.

Tracon Pharma Shares Rally As First Patient Dosed In Cancer Trial

TRACON Pharmaceuticals Inc. (TCON) CEO Charles Theuer on Q1 2019 Results - Earnings Call Transcript

TRACON Pharmaceuticals Inc (NASDAQ: TCON), a thinly traded nanocap biotech, is plunging Friday after it announced shelving of a study of a pipeline asset.

Nanocap Biotech Tracon Falls 50% After Shelving Study

Tracon Pharmaceuticals Inc. shares slid 45% in premarket trade Friday, after the company said it is terminating a late-stage trial of a cancer treatment at the recommendation of an independent committee.

Tracon Pharmaceuticals shares slide 45% premarket after it ends trial of cancer treatment

News for TRACON Pharmaceuticals Stock (TCON)